ANDA 200266, held by Apotex. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 200266 (Zolpidem Tartrate), held by Apotex, was first approved by FDA on Sep 10, 2013, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 10, 2013 | Original application | Approved | None posted |
| Zolpidem Tartrate6.25MG · tablet, extended release;oral | Zolpidem Tartrate | Discontinued |
| Zolpidem Tartrate12.5MG · tablet, extended release;oral | Zolpidem Tartrate | Discontinued |
| Nov 14, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 15, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 15, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 15, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 15, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 15, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 15, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 19, 2015 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 10, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters